Document Detail


Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
MedLine Citation:
PMID:  12783207     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The tyrosine kinase inhibitor imatinib mesylate inhibits the function of the Bcr-Abl oncoprotein associated with Philadelphia-positive chronic myelogenous leukemia (CML). Anagrelide suppresses megakaryocyte proliferation and differentiation. The objectives of this study were to investigate the feasibility and safety of imatinib mesylate and anagrelide combination therapy in patients with Ph-positive CML or chronic myeloproliferative disorders (MPD) with persistent thrombocythemia. METHODS: This study was a retrospective review of all available records of patients with chronic MPD presenting to the M.D. Anderson Cancer Center between October 1998 and May 2002, treated with imatinib mesylate combined with anagrelide. RESULTS: Of 22 patients identified, 18 had Ph-positive CML (chronic phase, 16 patients; accelerated phase, 2 patients), 1 had agnogenic myeloid metaplasia (AMM), 2 had essential thrombocythemia (ET) and 1 had MPD transformed into refractory anemia with excess blasts (RAEB). The median age was 57 years (range 26-82 years). The median dose of imatinib mesylate administered was 400 mg (range 300-800 mg) and the median dose of anagrelide was 1.5 mg (range 0.5-4.0 mg). Imatinib mesylate and anagrelide combination therapy was feasible and tolerable. Of the 18 patients with Ph-positive CML, 15 in chronic phase and 1 in accelerated phase achieved a complete hematologic response (CHR), and 9 of the 18 achieved cytogenetic response (complete in 8 patients). No responses were noted in patients with AMM, ET or MPD transformed into RAEB. CONCLUSIONS: The combination of imatinib mesylate and anagrelide was safe and was associated with an 89% CHR rate in patients with CML in chronic phase and persistent thrombocythemia.
Authors:
Apostolia M Tsimberidou; Dawn E Colburn; Mary Alma Welch; Jorge E Cortes; Srdan Verstovsek; Susan M O'Brien; Maher Albitar; Hagop M Kantarjian; Francis J Giles
Related Documents :
13426797 - The carcinolytic effect of actinomycin c; a report of clinical studies.
6594187 - Chromosome changes and splenectomy in ph1-positive chronic myeloid leukemia. i. predict...
6958357 - A summary of cytogenetic, morphologic, and clinical data on t(8q - ;21q+) and t(15q + ;...
9885207 - Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients.
3134807 - Cranial mr imaging in neurofibromatosis.
2763237 - Anginal chest pain in sarcoidosis.
Publication Detail:
Type:  Journal Article     Date:  2003-05-29
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  52     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-08-27     Completed Date:  2003-10-23     Revised Date:  2004-12-08    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  229-34     Citation Subset:  IM    
Affiliation:
Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Chronic Disease
Drug Therapy, Combination
Enzyme Inhibitors / adverse effects,  therapeutic use*
Female
Fibrinolytic Agents / adverse effects,  therapeutic use*
Humans
Male
Medical Records Systems, Computerized
Middle Aged
Myeloproliferative Disorders / drug therapy*,  mortality
Piperazines / adverse effects,  therapeutic use*
Pyrimidines / adverse effects,  therapeutic use*
Quinazolines / adverse effects,  therapeutic use*
Retrospective Studies
Survival Analysis
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Fibrinolytic Agents; 0/Piperazines; 0/Pyrimidines; 0/Quinazolines; 0/anagrelide; 152459-95-5/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Next Document:  Granisetron: is there a dose-response effect on nausea and vomiting?